Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib Plus Tamoxifen or Abemaciclib Alone in HR+, HER2- Metastatic Breast Cancer
NCT02747004Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of abemaciclib in breast cancer, sponsored by Eli Lilly and Company. Started Sep 2016; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02747004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02747004.